Abstract
Background: Pyrazoloacridine (PZA) is thefirst of a new class of rationallysynthesized acridine derivatives to undergoclinical testing as an anticancer agent. We previously demonstrated cytotoxicsynergy between combinations of PZA andplatinum compounds. Subsequent studiesrevealed that PZA inhibits removal ofplatinum-DNA adducts in cultured A549cells. Based on these results, weundertook a phase I study of thecombination of PZA and carboplatin (CBDCA).
Patients and methods: Twenty-eightpatients received 76 28-day courses (median2.5, range 1–6) of CBDCA (30-minuteinfusion) followed by PZA (3-hourinfusion), through six dose levels [PZA/CBDCA] (200/AUC 3,400/AUC 3, 400/AUC 4,400/AUC 5, 500/AUC 5, 600/AUC5 mg/m2/AUC). Pharmacokineticanalyses were performed to evaluate thedisposition of PZA. Retention ofplatinum-DNA adducts in peripheral bloodmononuclear cells of patients was alsoevaluated.
Results: The most common anddose-limiting toxicity wasmyelosuppression, consisting of neutropeniaand leukopenia. Non-hematologic toxicitiesof anorexia, nausea and stomatitis weremild to moderate. In six patientsevaluated at the MTD, CBDCA did not appearto affect the pharmacokinetics of PZA. Onepatient with malignant melanoma had apartial response. Disease stabilizationfor greater than 4 courses of treatmentoccurred in 4 patients.
Conclusion: The combination of PZAand CBDCA was well tolerated and may haveutility in some tumor types.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adjei A, Charron M, Rowinsky EK, Svingen PA, Miller J, Reid JM, Sebolt-Leopold J, Ames MM, Kaufmann SH: Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res 4(3):683–691, 1998
Sebolt J, Scavone S, Pinter C: Pyrazoloacridines, a new class of antitumor agents with selectivity against solid tumors in vitro. Cancer Res 47:4299–4304, 1987
LoRusso P, Wozniak AJ, Polin L: Antitumor efficacy of PD 115932 (NSC 366140) against solid tumors of mice. Cancer Res 50:4900–4905, 1990
Sebolt J, Havlick M, Hamelehle K: Activity of the pyrazoloacridines against multidrug-resistant tumor cells. Cancer Chemother Pharmacol 24:219–224, 1998
Cole SP: Patterns of cross-resistance in a multidrug-resistance small cell lung carcinoma line. Cancer Chemother Pharmacol 26:250–256, 1990
Rowinsky EK, Noe DA, Grochow LB, Sartorious E, Bowling MK, Chen TL, Lubejko BG, Kaufmann SH, Donehower RC: Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single and multiple dosing schedules. J Clin Oncol 13:1975–1984, 1995
LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L: Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). Clin Cancer Res 1:1487–1493, 1995
Monahan B, Quinn M, Takimoto C, Chen A, Hamilton JM, Harold N, Morrison G, Nguyen D, Grem J: Phase I trial of pyrazoloacridine (PZA), a potent DNA binding agent, given as a weekly 24 hour continuous intravenous infusion in adult patients with refractory solid tumors. Proc Am Soc Clin Oncol 17:736, 1998
Berg SL, Blaney SM, Adamson PC, O'Brien M, Poplack DG, Arndt C, Blatt J, Balis FM: Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol 16(1):181–186, 1998
Murgo AJ, Cannon D, Christian MC, Cheson B, Nelson AP: Clinical trials referral resource. Clinical trials with pyrazoloacridine. Oncology 11(7):991–994, 1997
Adjei AA: Current status of pyrazoloacridine as an anticancer agent. Invest New Drugs 17:43–48, 1999
Adjei AA, Budihardjo I, Rowinsky EK, Kottke TJ, Svingen PA, Buckwalter CA, Grochow LB, Donehower RC, Kaufmann SH: Cytotoxic synergy between pyrazoloacridine (NSC366140) and cisplatin in vitro: Inhibition of platinum-DNA adduct removal. Clin Cancer Res 3:761–770, 1997
Ratain MJ, Mick R, Schilsky RL, Siegler M: Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 85:1637–1643, 1993
Walker DL, Reid JM, Svingen PA, Rios R, Covey JM, Alley MC, Hollingshead MG, Budihardjo II, Eckdahl S, Boerner SA, Kaufmann SH, Ames MM: Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. Biochem Pharmacol 58:1057–1066, 1999
Gibaldi M, Perrier D: Analysis based on statistical moment theory. In: Pharmacokinetics, Edition 2, New York, Marcel Dekker, pp 409–417, 1982
Zalupski MM, Shields AF, Philip PA, Kraut M, LoRusso P, Heilbrun LK, Vaitkevicius V: Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Invest New Drugs 16(1):93–96, 1998
Small EJ, Fippin LJ, Whisenant SP: Pyrazoloacridine for the treatment of hormone-refractory prostate cancer. Cancer Invest 16(7):456–461, 1998
Zalupski MM, Philip PA, LoRusso P, Shields AF: Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Cancer Chemother Pharmacol 40(3): 225–227, 1997
Mani S, Gerstner JB, Wade JL, Vokes EE: Phase II trials of pyrazoloacridine (NSC 366140) in patients with advanced hepatobiliary and pancreatic cancer. Cancer Ther 1:313–317, 1998
Jackson R, Sebolt J, Shillis J: The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Invest 8:39–47, 1990
Jackson RC: The problem of the quiescent cancer cell. Adv Enzyme Regul 29:27–46, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Adjei, A.A., Reid, J.M., Erlichman, C. et al. A Phase I and Pharmacologic Study of Pyrazoloacridine (NSC 366140) and Carboplatin in Patients with Advanced Cancer. Invest New Drugs 20, 297–304 (2002). https://doi.org/10.1023/A:1016237426846
Issue Date:
DOI: https://doi.org/10.1023/A:1016237426846